Opportunity Information: Apply for RFA DK 27 301
The Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed) funding opportunity (RFA DK-27-301) is a National Institutes of Health cooperative agreement aimed at expanding and strengthening the KPMP network of clinical recruitment sites. The core purpose is to enroll people with acute kidney injury (AKI) and/or chronic kidney disease (CKD) into a longitudinal cohort study that includes kidney biopsies and deep clinical characterization over time. These recruitment sites are expected to serve as the front door for participant identification, consent, clinical data collection, biospecimen acquisition (including biopsy tissue), and ongoing follow-up so the program can build a high-quality, well-annotated resource for precision medicine discovery in kidney disease.
A major emphasis of this round is improving enrollment where there have historically been gaps, with AKI specifically called out as under-enrolled and therefore a priority population. Beyond simply increasing participant numbers, the NOFO stresses comprehensive phenotyping, meaning applicants should be prepared to capture detailed clinical context and relevant physiologic and laboratory information that can help interpret tissue-level and molecular findings. The intent is to connect what is seen in the kidney tissue to what is happening in the patient clinically, enabling more precise disease subtyping, improved understanding of mechanisms, and identification of targets for future interventions.
The announcement also highlights several expanded or newer participation opportunities for recruitment sites. These include the ability to leverage clinically indicated biopsies where residual tissue can be used for research, which may broaden feasibility and increase the diversity of samples obtained in real-world care settings. It also includes enhanced physiologic phenotyping, suggesting an interest in richer functional assessments beyond standard clinical measurements. In addition, the NOFO allows or encourages repeat biopsies in appropriate circumstances, which can be valuable for studying disease progression, treatment response, or changes over time. Pediatric recruitment is explicitly mentioned, signaling a push to include children and adolescents where scientifically and ethically appropriate, and to fill knowledge gaps in pediatric kidney disease. Another notable expansion is the collection of healthy reference tissue, which can strengthen interpretation of disease-associated findings by providing well-characterized baseline comparators.
This mechanism is a cooperative agreement (U01), which typically means the NIH expects substantial scientific and programmatic involvement during the award. In practice, recruitment sites should anticipate close coordination with the broader KPMP consortium, adherence to common protocols and data standards, participation in network governance and working groups, and responsiveness to evolving consortium needs. The NOFO also makes clear that KPMP personnel are expected to actively participate in scientific discovery and to promote open science, reflecting a commitment to broad data sharing, transparency, and collaborative analysis so that the resulting datasets and biospecimens can accelerate kidney research for the wider community.
Eligibility is broad across U.S.-based domestic entities and includes many common applicant types such as state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); small businesses; and other domestic organizations that meet NIH requirements. At the same time, the geographic restriction is explicit: non-U.S. entities are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed. Applicants are directed to consult Section III of the NOFO for any additional eligibility conditions or clarifications beyond these high-level rules.
In terms of funding and scale, the opportunity lists an expected eight awards, with an award ceiling of $450,000. The original application closing date is July 10, 2026, and the program is categorized under Health with CFDA number 93.847. Overall, the opportunity is designed for clinical centers and partner organizations capable of recruiting and longitudinally following AKI and CKD participants, performing or coordinating kidney biopsy-based research activities, and operating within a highly collaborative, standardized, open-science consortium environment.Apply for RFA DK 27 301
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on 2026-06-03.
- Applicants must submit their applications by 2026-07-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- The number of recipients for this funding is limited to 8 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity called?
The opportunity is titled Kidney Precision Medicine Project Recruitment Sites (U01 Clinical Trial Not Allowed) and is associated with RFA DK-27-301.
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What type of award mechanism is this?
This opportunity uses a cooperative agreement (U01) mechanism, which typically involves substantial NIH scientific and/or programmatic involvement during the project period.
Are clinical trials allowed under this opportunity?
No. The opportunity is labeled "Clinical Trial Not Allowed".
What is the main purpose of funding KPMP Recruitment Sites?
The core purpose is to expand and strengthen the KPMP network of clinical recruitment sites that enroll participants with acute kidney injury (AKI) and/or chronic kidney disease (CKD) into a longitudinal cohort study involving kidney biopsies and deep clinical characterization over time.
What is KPMP trying to build through these recruitment sites?
The program aims to build a high-quality, well-annotated resource to support precision medicine discovery in kidney disease, connecting tissue-level and molecular findings with detailed clinical context.
What participant populations are a priority for enrollment?
The announcement emphasizes improving enrollment in historically under-enrolled groups, with AKI specifically called out as under-enrolled and therefore a priority population.
What diseases or conditions should recruitment sites focus on?
Recruitment sites are expected to enroll participants with AKI and/or CKD into the KPMP longitudinal cohort.
What does "longitudinal cohort study" mean in this context?
In this opportunity, it refers to enrolling participants and then following them over time, including ongoing collection of clinical information and biospecimens (including biopsy tissue) to understand disease mechanisms and progression.
What roles are recruitment sites expected to play in KPMP?
Recruitment sites are described as the program's "front door" and are expected to support: participant identification, informed consent, clinical data collection, biospecimen acquisition (including biopsy tissue), and ongoing follow-up.
What kinds of data collection are emphasized in the NOFO?
The NOFO stresses comprehensive phenotyping, meaning the capture of detailed clinical context and relevant physiologic and laboratory information to help interpret kidney tissue and molecular findings.
Why is comprehensive phenotyping emphasized?
The intent is to connect what is seen in kidney tissue with what is happening clinically, enabling more precise disease subtyping, improved understanding of mechanisms, and identification of targets for future interventions.
Does the opportunity allow use of clinically indicated biopsies?
Yes. The announcement highlights the ability to leverage clinically indicated biopsies where residual tissue can be used for research, which may broaden feasibility and increase diversity of samples from real-world care settings.
Is enhanced physiologic phenotyping included in the scope?
Yes. The NOFO highlights enhanced physiologic phenotyping, indicating interest in richer functional assessments beyond standard clinical measurements.
Are repeat kidney biopsies permitted?
Yes. The NOFO allows or encourages repeat biopsies in appropriate circumstances, which can support studies of progression, treatment response, or changes over time.
Does the opportunity include pediatric recruitment?
Yes. Pediatric recruitment is explicitly mentioned, reflecting an intent to include children and adolescents when scientifically and ethically appropriate and to address knowledge gaps in pediatric kidney disease.
Is the collection of healthy reference tissue included?
Yes. The NOFO includes collection of healthy reference tissue to help interpret disease-associated findings by providing well-characterized baseline comparators.
What level of coordination with NIH and the KPMP consortium is expected?
As a U01 cooperative agreement, recruitment sites should anticipate close coordination with the broader KPMP consortium, including adherence to common protocols and data standards, participation in governance and working groups, and responsiveness to evolving consortium needs.
What does the opportunity say about open science and data sharing?
The announcement states that KPMP personnel are expected to actively participate in scientific discovery and to promote open science, reflecting a commitment to broad data sharing, transparency, and collaborative analysis to accelerate kidney research for the wider community.
Who is eligible to apply?
Eligibility is broad for U.S.-based domestic entities, including (as listed in the opportunity): state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including those other than small businesses); small businesses; and other domestic organizations that meet NIH requirements.
Are non-U.S. (foreign) organizations eligible to apply?
No. The geographic restriction is explicit: non-U.S. entities are not eligible to apply.
Can a U.S. organization include a non-U.S. component on the application?
No. The opportunity states that non-U.S. components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The announcement states that foreign components (as defined by NIH policy) are not allowed.
Where should applicants look for additional eligibility conditions?
Applicants are directed to consult Section III of the NOFO for any additional eligibility conditions or clarifications.
How many awards are expected?
The opportunity lists an expectation of eight awards.
What is the award ceiling?
The opportunity lists an award ceiling of $450,000.
What is the application due date?
The original application closing date is July 10, 2026.
What is the CFDA number and program category?
The program is categorized under Health with CFDA number 93.847.
What types of organizations are this opportunity designed for?
It is designed for clinical centers and partner organizations capable of recruiting and longitudinally following AKI and CKD participants, performing or coordinating kidney biopsy-based research activities, and operating within a highly collaborative, standardized, open-science consortium environment.
Browse more opportunities from the same category: Health
Next opportunity: Rural Northern Border Region Network Planning Program
Previous opportunity: Centers for Independent Living Competition - American Samoa
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 27 301
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 27 301) also looked into and applied for these:
| Funding Opportunity |
|---|
| Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed) Apply for RFA DK 27 302 Funding Number: RFA DK 27 302 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional) Apply for RFA DK 27 120 Funding Number: RFA DK 27 120 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Single Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed) Apply for RFA NS 27 011 Funding Number: RFA NS 27 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional) Apply for PAS 27 028 Funding Number: PAS 27 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Kidney Precision Medicine Project Central Hub (U24 Clinical Trial Not Allowed) Apply for RFA DK 27 303 Funding Number: RFA DK 27 303 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Growing Great Ideas: Research Education Course in Entrepreneurship and Product Development for Researchers Studying Drug Use, Drug Misuse, and Drug Addiction (UE5 Clinical Trial Not Allowed) Apply for RFA DA 27 007 Funding Number: RFA DA 27 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 055 Funding Number: PAR 27 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Preventing global health threats by strengthening surveillance systems to accelerate outbreak detection, notification, and response Apply for CDC RFA JG 26 0113 Funding Number: CDC RFA JG 26 0113 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) Apply for RFA DK 27 108 Funding Number: RFA DK 27 108 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Kidney, Urologic, and Hematologic Diseases - Fostering the AdvanceMent of an Interactive Learning communitY - Coordinating Center (KUH-FAMILY) (U24- Clinical Trials Not Allowed) Apply for RFA DK 27 126 Funding Number: RFA DK 27 126 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases Apply for CDC RFA CK 26 0107 Funding Number: CDC RFA CK 26 0107 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $30,000,000 |
| Strengthening tuberculosis (TB) prevention, diagnosis, treatment, and surveillance in Asia Apply for CDC RFA JG 26 0125 Funding Number: CDC RFA JG 26 0125 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Enhancing sustainable health information and laboratory systems and networks for quality detection, management, and monitoring to end HIV and TB as public health threats in India Apply for CDC RFA JG 26 0143 Funding Number: CDC RFA JG 26 0143 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Sustaining life-saving HIV services in Ukraine by strengthening resilient health systems under the Ukraine Ministry of Health, Public Health Center Apply for CDC RFA JG 26 0172 Funding Number: CDC RFA JG 26 0172 Agency: Centers for Disease Control-GHC Category: Health Funding Amount: Case Dependent |
| Atopic Dermatitis Research Network (ADRN) (U19 Clinical Trial Optional) Apply for RFA AI 27 004 Funding Number: RFA AI 27 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Metastasis Research Network (U54 Clinical Trial Not Allowed) Apply for RFA CA 27 012 Funding Number: RFA CA 27 012 Agency: National Institutes of Health Category: Health Funding Amount: $1,300,000 |
| Seed Instrumentation Support (SIS) Program (S10 Clinical Trial Not Allowed) Apply for PAR 27 021 Funding Number: PAR 27 021 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Reducing the burden of parasitic infections in the United States through evidence-based prevention and control activities. Apply for CDC RFA CK 26 0221 Funding Number: CDC RFA CK 26 0221 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,250,000 |
| Increasing awareness and knowledge of Alpha-gal Syndrome in the United States Apply for CDC RFA CK 26 0193 Funding Number: CDC RFA CK 26 0193 Agency: Centers for Disease Control - NCEZID Category: Health Funding Amount: $1,000,000 |
| National Child Traumatic Stress Initiative - Treatment and Service Adaptation (TSA) Centers Apply for SM 26 003 Funding Number: SM 26 003 Agency: Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $600,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 27 301", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.